INSYS Therapeutics Appoints Elizabeth Bohlen to Board of Directors
PHOENIX, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Elizabeth Bohlen as a new independent member of its Board of Directors.
Ms. Bohlen is the chief operating officer of the Archdiocese of Chicago, where she oversees the organization’s administrative functions. She joined the Archdiocese in 2011 after 16 years at McKinsey & Co., where, as a partner, she provided strategic counsel to multinational companies across the retail, consumer and healthcare industries.
“I am delighted that Betsy has joined the Board and brings her expertise in business strategy and organizational transformation to INSYS,” said Steven Meyer, chairman of the INSYS Therapeutics Board of Directors. “We look forward to the benefit of her counsel as we continue to evolve INSYS into a leader in pharmaceutical cannabinoids and novel drug delivering systems to address serious unmet medical needs.”
Prior to assuming her current role in 2015, Ms. Bohlen served in a variety of other leadership positions at the Archdiocese of Chicago, including chief financial officer. She began her career as a financial analyst at The First Boston Corp. (now CSFB) and later worked at McKinsey as a management consultant from 1995 to 2011. Her education includes a B.A. in economics from the University of Notre Dame and an M.B.A. from Harvard Business School.
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating anaphylaxis, epilepsy, Prader-Willi syndrome, opioid addiction and overdose, and other disease areas with a significant unmet need.
This news release contains forward-looking statements including regarding our belief in Ms. Bohlen’s leadership experience. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2017 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
|CONTACT:||Corporate Communications||Investor Relations|
|Joe McGrath||Jackie Marcus or Chris Hodges|
|INSYS Therapeutics||Alpha IR Group|